New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 27, 2010
14:19 EDTMCK, SNY, HSP, ABCRumor: Pharma Distributors move up on speculation of a positive court ruling
Shares of Hospira (HSP), McKesson (MCK) and AmerisourceBergen (ABC) are moving higher on conjecture that a District Court declared Sanofi's patents invalid, clearing the way for generic Taxotere.
News For HSP;MCK;ABC;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
07:22 EDTABCUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
May 17, 2015
14:59 EDTSNYL'Oreal CEO 'ready' to sell Sanofi stake if needed, Barron's says
Subscribe for More Information
May 15, 2015
12:13 EDTMCKThird Point gives quarterly update on stakes
NEW STAKES: Yum! Brands (YUM), NXP Semiconductors (NXPI), FedEx (FDX), McKesson (MCK), and J M Smucker (SJM). INCREASED STAKES: Actavis (ACT), Roper Technologies (ROP), Delta Air Lines (DAL), and FleetCor Technologies (FLT). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Phillips 66 (PSX), eBay (EBAY), and Anheuser Busch Inbev SA (BUD). LIQUIDATED STAKES: Alibaba Group (BABA), Citigroup (C), EMC Corporation (EMC), Anglo American (AAL), and Williams Companies (WMB).
12:07 EDTMCKThird Point reports new stakes in Yum! Brands, FedEx, McKesson
10:29 EDTSNYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
May 14, 2015
12:29 EDTHSPPfizer receives 'second request' from FTC regarding potential Hospira merger
Subscribe for More Information
May 13, 2015
19:17 EDTHSPHospira and FDA detect security vulnerabilities in infusion pumps
Subscribe for More Information
13:43 EDTHSPHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.
10:07 EDTMCKHigh option volume stocks
Subscribe for More Information
09:56 EDTMCKEquity options with increasing volume
Subscribe for More Information
09:12 EDTABCAmerisourceBergen price target raised to $135 from $104 at Argus
Subscribe for More Information
08:54 EDTMCKMcKesson price target raised to $252 from $234 at Cowen
Subscribe for More Information
07:55 EDTMCKMcKesson Q4 results 'outstanding,' says Baird
Subscribe for More Information
07:31 EDTSNY, MCKHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
May 12, 2015
16:20 EDTMCKMcKesson authorizes $500M repurchase program
Subscribe for More Information
16:18 EDTMCKMcKesson sees FY16 EPS $12.20-$12.70, consensus $12.57
Sees FY16 distribution solutions revenue growth in mid-single digits. Sees North America pharmaceutical distribution and services delivering high-single digit revenue growth. Sees international pharmaceutical and distribution services revenues flat year-over-year on constant currency basis. Sees medical-surgical distribution and services delivering mid-single digit revenue growth. Sees branded drug price trends in U.S. similar to FY15. Sees price trends on generic drugs outside an exclusivity period, in the U.S. market, slightly below FY15. Sees profit contribution from launch of new oral generic pharmaceuticals in the U.S. market decreasing. Sees technology solutions revenue declining mid-single digits driven by revenue decline in our hospital software business and pending sale of a business line. Guidance assumes adjusted tax rate 31.5%. Sees cash flow from operations $3B.
16:14 EDTMCKMcKesson reports Q4 adjusted adjusted EPS $2.94, consensus $2.75
Subscribe for More Information
15:00 EDTMCKNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include McKesson (MCK), consensus $2.75... Zillow (Z), consensus (12c)... GoDaddy (GDDY), consensus 35c... RSP Permian (RSPP), consensus 17c... Parsley Energy (PE), consensus 0c... Vivint Solar (VSLR), consensus (38c)... New Relic (NEWR), consensus (25c)... Hortonworks (HDP), consensus (86c)... SunOpta (STKL), consensus 7c... OPOWER (OPWR), consensus (16c)... JP Energy Partners (JPEP), consensus (4c)... TubeMogul (TUBE), consensus (18c)... Ducommun (DCO), consensus 30c.
07:56 EDTMCKMcKesson has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO John Hammergren on May 13 at 10:30 am.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use